UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005272
Receipt number R000006269
Scientific Title A fact-finding study on the treatment of gastroesophageal reflux disease (GERD) - Retrospective study on therapeutic effects of proton pump inhibitors on reflux esophagitis -
Date of disclosure of the study information 2011/03/18
Last modified on 2011/08/29 17:22:55

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A fact-finding study on the treatment of gastroesophageal reflux disease (GERD)
- Retrospective study on therapeutic effects of proton pump inhibitors on reflux esophagitis -

Acronym

A retrospective fact-finding study on the treatment of gastroesophageal reflux disease (GERD)

Scientific Title

A fact-finding study on the treatment of gastroesophageal reflux disease (GERD)
- Retrospective study on therapeutic effects of proton pump inhibitors on reflux esophagitis -

Scientific Title:Acronym

A retrospective fact-finding study on the treatment of gastroesophageal reflux disease (GERD)

Region

Japan


Condition

Condition

gastroesophageal reflux disease (GERD)

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To determine any Grade A to D esophageal erosions according to the modified Los Angeles classification (LA classification) retrospectively based on a review of medical records of patients with reflux esophagitis treated with a proton pump inhibitor (PPI)

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase



Assessment

Primary outcomes

Esophageal endoscopic findings after at least eight weeks of treatment with any of the drugs surveyed

Key secondary outcomes

Factors that may affect cure of lesions (e.g., sex, age, BMI, duration of disease, LA grade, acid reflux-related symptoms, H. pylori, PPI dose)


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

To be eligible for this study, patients must have undergone endoscopy between August 2005 and July 2010, meet all of the following inclusion criteria, and not meet any of the key exclusion criteria:
- Patients of both sexes aged 20 years and above
- Patients who received eight-week or longer treatment with any of the designated PPIs (i.e., drugs surveyed) of omeprazole, lansoprazole, or rabeprazole
- Patients with endoscopically confirmed Grade A or worse reflux esophagitis according to the LA classification within four weeks before PPI therapy
- Patients who underwent endoscopy after at least eight weeks of PPI therapy, for whom records are available on findings according to the LA classification. The endoscopic findings must have been obtained from endoscopy conducted during PPI therapy or within four weeks after the end of PPI therapy.

Key exclusion criteria

1) Patients who had a history of gastrointestinal resection or vagotomy
2) Patients who had a concurrent malignant lesion
3) Patients who had a prior or current history of any of the following diseases:
- Esophageal stricture
- Eosinophilic reflux esophagitis
- Esophageal achalasia
- Malabsorption

Target sample size

500


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Ken Haruma

Organization

Kawasaki Medical School

Division name

Gastroenterology, Ultrasonography, and Translational Medicine & Nutrition

Zip code


Address

577 Matsushima, Kurashiki, Okayama 701-0192, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

GERD Society

Division name

Secretariat

Zip code


Address


TEL


Homepage URL


Email

gerd@mcp.co.jp


Sponsor or person

Institute

GERD Society

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

川崎医科大学(岡山県) 他51施設(予定)


Other administrative information

Date of disclosure of the study information

2011 Year 03 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2010 Year 09 Month 10 Day

Date of IRB


Anticipated trial start date

2010 Year 12 Month 01 Day

Last follow-up date

2011 Year 07 Month 01 Day

Date of closure to data entry

2011 Year 08 Month 01 Day

Date trial data considered complete

2011 Year 08 Month 01 Day

Date analysis concluded

2011 Year 09 Month 01 Day


Other

Other related information

A multicenter prospective survey

1) Survey drugs
Omeprazole tablet 20mg or 10mg
Lansoprazole Capsule or OD tablet 15mg or 30mg
Rabeprazole tablet 10mg or 20mg
2) Survey records
Medical redords containing at least two endoscopic results obtained between August 2005 and July 2010


Management information

Registered date

2011 Year 03 Month 17 Day

Last modified on

2011 Year 08 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006269


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name